These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 24667376)

  • 1. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
    Tao JJ; Castel P; Radosevic-Robin N; Elkabets M; Auricchio N; Aceto N; Weitsman G; Barber P; Vojnovic B; Ellis H; Morse N; Viola-Villegas NT; Bosch A; Juric D; Hazra S; Singh S; Kim P; Bergamaschi A; Maheswaran S; Ng T; Penault-Llorca F; Lewis JS; Carey LA; Perou CM; Baselga J; Scaltriti M
    Sci Signal; 2014 Mar; 7(318):ra29. PubMed ID: 24667376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
    Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
    Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
    Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
    Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
    Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
    Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
    Garner AP; Bialucha CU; Sprague ER; Garrett JT; Sheng Q; Li S; Sineshchekova O; Saxena P; Sutton CR; Chen D; Chen Y; Wang H; Liang J; Das R; Mosher R; Gu J; Huang A; Haubst N; Zehetmeier C; Haberl M; Elis W; Kunz C; Heidt AB; Herlihy K; Murtie J; Schuller A; Arteaga CL; Sellers WR; Ettenberg SA
    Cancer Res; 2013 Oct; 73(19):6024-35. PubMed ID: 23928993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.
    Li C; Huang S; Armstrong EA; Francis DM; Werner LR; Sliwkowski MX; van der Kogel A; Harari PM
    Mol Cancer Ther; 2015 Sep; 14(9):2049-59. PubMed ID: 26141946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
    Choi BK; Fan X; Deng H; Zhang N; An Z
    Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.
    Huang S; Li C; Armstrong EA; Peet CR; Saker J; Amler LC; Sliwkowski MX; Harari PM
    Cancer Res; 2013 Jan; 73(2):824-33. PubMed ID: 23172311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
    Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
    Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
    Meister KS; Godse NR; Khan NI; Hedberg ML; Kemp C; Kulkarni S; Alvarado D; LaVallee T; Kim S; Grandis JR; Duvvuri U
    Sci Rep; 2019 Jun; 9(1):9130. PubMed ID: 31235758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
    Junttila TT; Akita RW; Parsons K; Fields C; Lewis Phillips GD; Friedman LS; Sampath D; Sliwkowski MX
    Cancer Cell; 2009 May; 15(5):429-40. PubMed ID: 19411071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
    Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
    Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
    Lazrek Y; Dubreuil O; Garambois V; Gaborit N; Larbouret C; Le Clorennec C; Thomas G; Leconet W; Jarlier M; Pugnière M; Vié N; Robert B; Monnet C; Bouayadi K; Kharrat H; Mondon P; Pèlegrin A; Chardès T
    Neoplasia; 2013 Mar; 15(3):335-47. PubMed ID: 23479511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency.
    Fu W; Lei C; Yu Y; Liu S; Li T; Lin F; Fan X; Shen Y; Ding M; Tang Y; Ye X; Yang Y; Hu S
    Clin Cancer Res; 2019 May; 25(9):2835-2847. PubMed ID: 30670492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
    Garrett JT; Sutton CR; Kurupi R; Bialucha CU; Ettenberg SA; Collins SD; Sheng Q; Wallweber J; Defazio-Eli L; Arteaga CL
    Cancer Res; 2013 Oct; 73(19):6013-23. PubMed ID: 23918797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation.
    Okano J; Gaslightwala I; Birnbaum MJ; Rustgi AK; Nakagawa H
    J Biol Chem; 2000 Oct; 275(40):30934-42. PubMed ID: 10908564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma.
    Guo T; Wu C; Zhang J; Yu J; Li G; Jiang H; Zhang X; Yu R; Liu X
    Cell Commun Signal; 2023 Dec; 21(1):363. PubMed ID: 38115126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.